MedinCell Future Growth
Future criteria checks 5/6
MedinCell is forecast to grow earnings and revenue by 93.9% and 46.2% per annum respectively while EPS is expected to grow by 70.9% per annum.
Key information
93.9%
Earnings growth rate
70.9%
EPS growth rate
Pharmaceuticals earnings growth | 17.6% |
Revenue growth rate | 46.2% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 30 Sep 2024 |
Recent future growth updates
Recent updates
MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be
Jul 05Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%
Apr 26Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher
Jan 09The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On
Mar 02Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?
Jan 08Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 88 | 38 | 32 | 29 | 1 |
3/31/2026 | 39 | 11 | 7 | 15 | 4 |
3/31/2025 | 24 | -11 | 3 | 3 | 5 |
3/31/2024 | 12 | -25 | -13 | -12 | N/A |
12/31/2023 | 13 | -26 | -18 | -17 | N/A |
9/30/2023 | 14 | -26 | -24 | -23 | N/A |
6/30/2023 | 14 | -29 | -23 | -22 | N/A |
3/31/2023 | 14 | -32 | -22 | -21 | N/A |
12/31/2022 | 13 | -29 | -22 | -21 | N/A |
9/30/2022 | 12 | -27 | -22 | -20 | N/A |
6/30/2022 | 10 | -26 | -23 | -21 | N/A |
3/31/2022 | 8 | -25 | -23 | -21 | N/A |
12/31/2021 | 9 | -22 | -21 | -19 | N/A |
9/30/2021 | 9 | -20 | -18 | -17 | N/A |
6/30/2021 | 9 | -19 | -15 | -14 | N/A |
3/31/2021 | 8 | -19 | -13 | -12 | N/A |
12/31/2020 | 7 | -22 | -12 | -11 | N/A |
9/30/2020 | 5 | -26 | -11 | -10 | N/A |
6/30/2020 | 6 | -25 | -12 | -11 | N/A |
3/31/2020 | 6 | -24 | -13 | -13 | N/A |
12/31/2019 | 6 | -21 | -16 | -16 | N/A |
9/30/2019 | 6 | -19 | -19 | -19 | N/A |
6/30/2019 | 5 | -19 | -18 | -17 | N/A |
3/31/2019 | 4 | -20 | -17 | -16 | N/A |
12/31/2018 | 6 | -17 | -12 | -11 | N/A |
9/30/2018 | 7 | -15 | -8 | -7 | N/A |
6/30/2018 | 8 | -12 | -7 | -6 | N/A |
3/31/2018 | 8 | -10 | -7 | -5 | N/A |
3/31/2017 | 10 | -4 | N/A | -3 | N/A |
3/31/2016 | 9 | 1 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MEDCL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).
Earnings vs Market: MEDCL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MEDCL is expected to become profitable in the next 3 years.
Revenue vs Market: MEDCL's revenue (46.2% per year) is forecast to grow faster than the French market (5.6% per year).
High Growth Revenue: MEDCL's revenue (46.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MEDCL's Return on Equity is forecast to be high in 3 years time